The University of Oxford, King’s College London and Smith+Nephew are bringing their expertise together to help the NHS fight COVID-19.

1 April 2020

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today confirms that it is contracting with the UK government to build OxVent ventilators.

The OxVent ventilator results from a collaboration of scientists, clinicians and medical technology manufacturers from the University of Oxford, King’s College London and Smith+Nephew. The ventilator has been designed to allow for large scale production.

The OxVent ventilator is currently under review by the Medicines and Healthcare products Regulatory Authority (MHRA) and the order is subject to the design gaining authorisation.

Smith+Nephew is supporting the assessment process and preparing for manufacture to begin immediately following authorisation from MHRA. The OxVent ventilator will be made at Smith+Nephew’s Advanced Wound Management facility in Hull, UK.

Roland Diggelmann, Chief Executive Officer of Smith+Nephew, said:

“We are proud to be able to support this vital effort and help meet the UK Government’s ventilator challenge to ensure the NHS is equipped for treating patients with COVID-19. I want to thank all our employees who are working long hours to make this happen, while also ensuring continued production of the important medical products already manufactured at our Hull site to support other patients. Our Purpose is Life Unlimited and I can think of no greater expression of this in practice.”

 

Enquiries

Investors

Andrew Swift                                                         +44 (0) 1923 477433
Smith+Nephew

 

Media

Charles Reynolds                                                   +44 (0) 1923 477314
Smith+Nephew

Susan Gilchrist / Ayesha Bharmal                           +44 (0) 207404 5959 Brunswick

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on TwitterLinkedInInstagram or Facebook.

 

Forward-looking Statement

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

SOURCE: Smith + Nephew, 1st April 2020

Fiona Walters

Author Fiona Walters

Executive Search Specialist fionawalters@orthocg.com

More posts by Fiona Walters